ArticleSexually transmitted infections2025
Stakeholder perspectives on integrating doxycycline postexposure prophylaxis into Kenyan HIV PrEP programmes.
Article in Sexually transmitted infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesDoxycycline postexposure prophylaxis (doxyPEP) is an efficacious sexually transmitted infection (STI) prevention strategy. Implementation guidelines recommend a focus on people with prior STIs and/or those taking HIV pre-exposure prophylaxis (PrEP), but trial results are insufficient for interventions to enter guidelines and clinical practice. The purpose of this paper is to describe potential barriers and facilitators for successful implementation strategies of doxyPEP in resource-limited settings.
methodsThis qualitative study explored the perceived acceptability, feasibility and sustainability of integrating doxyPEP for STI prevention into Kenyan HIV PrEP programmes. Semistructured interviews were conducted with policymakers, healthcare providers and HIV PrEP users. The interviews were recorded, transcribed and translated to English. Analysis was completed using Dedoose software using deductive reasoning based on the Consolidated Framework for Implementation Research.
resultsForty interviews (7 policymakers, 16 HIV PrEP users, 17 healthcare providers) were conducted between August 2022 and April 2023. Collectively, study participants found doxyPEP to be an acceptable strategy and understood its potential use among HIV PrEP users. However, participants noted several considerations such as the relative advantage, quality and evidence strength, and tension for change alongside the needs, resources and knowledge of the recipient. Integrating doxyPEP into HIV PrEP programmes was deemed feasible, but there were concerns over long-term sustainability, antimicrobial resistance (AMR), surveillance, cost, pill burden and compatibility, and high workload for HIV PrEP providers. Establishing sustainable practice needs to consider costs, external policies, incentives to participate and engaging providers and recipients in the process.
conclusionKenyan HIV/STI policymakers, healthcare providers and HIV PrEP users perceived doxyPEP for STI prevention to be acceptable and feasible when addressing local contextual factors. Potential for sustainability was recognised if programmes can address concerns, including AMR, pill burden and additional workload for health professionals, prior to the implementation of doxyPEP into HIV PrEP programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.